Bayer’s BAY-3389934 allows optimal controllability in sepsis-induced coagulopathy treatment
April 9, 2025
Sepsis-induced coagulopathy (SIC) is a complication of sepsis tied to high mortality in patients. Anticoagulation using a coagulation factor IIa and Xa dual inhibitor might have the potential to improve the treatment of this severe condition.